IV iron in heart failure most consistently cut hospital stays, an umbrella review finds

Intravenous iron for heart failure with iron deficiency most consistently reduced heart failure hospitalizations, while effects on survival remained uncertain, according to an umbrella review of forty-five reviews published Oct. 8, 2026, in Frontiers in Cardiovascular Medicine. It supports checking iron in heart failure.

Iron deficiency is common in heart failure, even without anemia. It’s linked to fatigue, shortness of breath, poorer quality of life and more hospital stays. Iron pills are poorly absorbed in heart failure, so intravenous iron has been tested in several trials, and many reviews have tried to summarize them, with conclusions that don’t always agree.

What did the study do?

Researchers searched six databases from 2016 to March 31, 2026, for systematic reviews and meta-analyses of iron for heart failure with iron deficiency. They found forty-five reviews and analyzed 18 representative ones in detail, judging their quality and checking how often the same trials were counted more than once. In total, the reviews drew on 23 unique randomized trials.

What did the study find about heart failure?

• Intravenous iron showed the most consistent link with fewer heart failure hospitalizations, with moderate certainty.
• Effects on death from any cause or from heart disease remained inconsistent.
• Effects on exercise capacity and quality of life were generally favorable but uncertain, with very low certainty.
• No clear increase in serious side effects was found.
• Most evidence came from people with reduced heart pumping function.
• The quality of the reviews themselves was often weak: low in seven and critically low in eleven.

Why does this matter?

Intravenous iron is now part of many heart failure guidelines. This review supports its role in reducing hospital stays, while warning that claims about longer survival go beyond the evidence and that many reviews recycle the same trials.

How solid is this evidence?

It’s moderate. Mongevity rates it C on our A-to-E scale: an umbrella review that carefully assessed quality and overlap, but it relies on reviews that were often of low quality, with substantial redundancy and inconsistent outcome definitions.

What are the open questions?

It’s still uncertain whether intravenous iron lowers mortality, which iron formulations work best and whether benefits extend to people with preserved heart function.

What does this mean for you?

If you have heart failure and feel very tired or short of breath, ask your doctor whether your iron levels, ferritin and transferrin saturation, have been checked. Intravenous iron may be an option if they’re low.

How do I explain this at dinner?

Many people with heart failure are low on iron. Giving iron through a drip seems to keep them out of the hospital more often, but whether it helps them live longer is still unclear. A good question for the table: what’s the difference between feeling better and living longer?

In one sentence: intravenous iron in heart failure with iron deficiency most consistently reduced heart failure hospitalizations, while effects on survival and function remain uncertain.